Live Cipla Share Price Chart
O H L VOL
Days Range
Data is not available currently. Please check back later.
Data is not available currently. Please check back later.
About Cipla
History of Cipla
Cipla Ltd was incorporated in 1935 as Chemical, Industrial & Pharmaceutical Laboratories Ltd. The founder of Cipla, Khwaja Abdul Hamied, gave the company all his patents and proprietary formulas for multiple drugs and medicines royalty-free. On August 17, 1935, the company was registered as a public limited company. Starting with its first manufacturing unit at Bombay Central in 1936, Cipla currently has over 40 state-of-the-art manufacturing facilities globally, including in countries like the USA, China, and South Africa, along with India. In 1941, Cipla took advantage of the shortage in drug supply due to the Second World War by producing fine chemicals. In 1952, the company set up its first research division. In 1968, it manufactured ampicillin for the first time in India. In the year 1972, Cipla started the Agricultural Research Division at Bangalore for scientific cultivation of medicinal plants. In the year 1985, US FDA approved the pharma company's bulk drug manufacturing facilities. Over time, Cipla has become one of the biggest global brands, with multiple facilities and products launched over the years.Business Segments of Cipla
Cipla is the third-largest pharmaceutical company in India. One of the biggest product categories of Cipla is finished medicines. The company has a diversified portfolio of more than 1,500 products in over 50 dosage forms and 65 therapeutic categories. It is a market leader in therapies such as those in respiratory and urology. It is also the 2nd largest Indian exporter in emerging markets, including the market in South Africa. Cipla is also a major producer of APIs or active pharmaceutical ingredients. It partners with major generic pharmaceutical companies in order to support their supply chain. Geographically, the market in India counts for slightly less than 50% of its revenues, while North America provides around 22% as of September 2023. In 2021, it had around 55 subsidiary companies. The list includes both domestic subsidiaries like Meditab Specialities Pvt. Ltd. and Cipla BioTec Pvt. Ltd., as well as foreign subsidiaries such as Cipla BioTec South Africa (Pty) Limited and InvaGen Pharmaceuticals Inc.Key Personnel of Cipla
- Mr. Umang Vohra, Managing Director & Global Chief Executive Officer
Corporate Actions
The following are some of the key corporate actions undertaken by Cipla in the past few years: Bonus Shares Cipla had last announced a bonus share issue in 2006 in the ratio of 3:2. Split Stocks Cipla had last split the face value of its shares from ₹10 to ₹2 in 2004. Cipla has not had any rights issues or buyback of shares.Mergers and Acquisitions
- During FY 2018, Anmarate (Pty) Limited was acquired in South Africa as a part of a strategy to strengthen its OTC portfolio.
- In February 2016, Cipla‘s UK arm, Cipla (EU) Limited, successfully completed the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc.
- In July 2013, Cipla acquired 100% of the issued shares of Cipla Medpro South Africa Ltd. for ZAR 4507 million (₹2,707 crore).
Management Outlook
In 2020-23, Cipla optimised its business models, restructured its portfolio, and strengthened its competitive position in key geographies. Throughout the pandemic, Cipla upscaled its capabilities to ensure the widespread availability of quality medicines. The company has also invested in automation and digitisation to drive sustainable efficiencies across its portfolio selection, manufacturing, supply chain, and quality operations.Parent Organisation
Indian Private
Managing Director
Y K Hamied
Founded
1935
NSE Symbol
CIPLA
Community Discussion
A
AngelOne
27th Mar, 2024
Cipla empowers Sanofi India’s CNS brands with exclusive partnership
Explore how Sanofi India’s exclusive partnership with Cipla for CNS product distribution aims to enhance patient access, leveraging Cipla’s extensive network and Sanofi’s established CNS brands.
Sanofi India has recently announced an exclusive partnership with Cipla, a leading pharmaceutical company, for the distribution and promotion of its central nervous system (CNS) product range in India. This strategic collaboration aims to enhance access to high-quality CNS treatments for patients across the country.
Partnership Details
Under the partnership, Cipla will be responsible for distributing Sanofi India’s six CNS brands, including the popular anti-epileptic medication Frisium. While Sanofi India will retain ownership and manufacturing responsibilities for its CNS products, Cipla will leverage its extensive network of marketing and sales professionals, distributors, and institutions to expand the reach of these treatments.
Sanofi India’s Perspective
Rodolfo Hrosz, Managing Director of Sanofi India, expressed confidence in Cipla’s capabilities to expand the reach of their CNS product portfolio. He emphasized the importance of this partnership in improving access to these life-changing treatments for patients across India.
Cipla’s Commitment to Accessibility
Achin Gupta, CEO of Cipla’s One India Business, highlighted the company’s commitment to enhancing access to high-quality treatments. He expressed enthusiasm for collaborating with Sanofi India to address the unmet needs of patients in the CNS therapy area.
Industry Impact
The CNS therapy area is known for its challenges, and this partnership between Sanofi India and Cipla is seen as a significant step forward in addressing these challenges. The collaboration is expected to bring value to patients by improving access to efficacious and quality therapeutic solutions.
Sanofi India’s Product Portfolio
Sanofi India offers a wide range of medicines across therapy areas such as diabetes, cardiology, thrombosis, CNS, and anti-histamines. The company’s products are distributed in India and exported to various countries around the world.
Cipla’s Global Presence
Cipla is a global pharmaceutical company with a focus on agile and sustainable growth. The company’s presence extends to markets such as India, South Africa, North America, and key regulated and emerging markets.
Market Performance
As of the latest trading session, Cipla was trading at Rs 1478.45 (+0.42%) at the National Stock Exchange (NSE), while Sanofi India was trading at Rs 8040 (+4.30%). These stock movements reflect the market’s positive reaction to the partnership announcement.
Conclusion
The partnership between Sanofi India and Cipla represents a significant development in the Indian pharmaceutical industry. By leveraging each other’s strengths, the two companies aim to improve access to high-quality CNS treatments and address the unmet needs of patients across India.
Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
0 Likes
0 Replies
Popular stocks
Cipla Ltd FAQs
What is the share price of Cipla Ltd (CIPLA) shares?
Cipla Ltd (CIPLA) share price as of October 9, 2024, on NSE is Rs 1689.2 (NSE) and Rs 1689.2 (BSE) on BSE.
Can I buy Cipla Ltd (CIPLA) from Angel One?
Yes, You can buy Cipla Ltd (CIPLA) shares by opening a Demat account with Angel One.
How do I buy Cipla Ltd (CIPLA) from Angel One?
Cipla Ltd (CIPLA) share can be bought through the following modes:
1. Direct investment: You can buy Cipla Ltd (CIPLA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Cipla Ltd (CIPLA) shares.
1. Direct investment: You can buy Cipla Ltd (CIPLA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Cipla Ltd (CIPLA) shares.
What is the main business of Cipla?
Indian multinational pharmaceutical business Cipla Limited is based in Mumbai. Cipla focuses on creating medications to treat a variety of illnesses, including arthritis, diabetes, depression, cardiovascular disease, respiratory diseases, and many others.
Who are the promoters of Cipla?
Yusuf Khwaja Hamied (18.77%), Sophie Ahmed (5.73%), Mustafa Khwaja Hamied (3.47%) are some of the biggest promoters of Cipla.
Open Free Demat Account!
Enjoy ₹0 Account Opening Charges
Join our 2 Cr+ happy customers